See What HealthDay Can Do For You
Contact Us

High Serum 25(OH)D Linked to Lower Breast Cancer Mortality

Meta-analysis shows lower risk of death from breast cancer with higher serum concentrations of 25(OH)D

High Serum 25(OH)D Linked to Lower Breast Cancer Mortality

FRIDAY, March 14, 2014 (HealthDay News) -- Higher concentrations of serum 25-hydroxyvitamin D (25[OH]D) are associated with lower mortality from breast cancer, according to a meta-analysis published in the March issue of Anticancer Research.

Sharif B. Mohr, M.P.H., from the Naval Health Research Center in San Diego, and colleagues conducted a meta-analysis of five studies to examine the correlation between 25(OH)D at diagnosis and mortality from breast cancer. A random-effects model was used to calculate hazard ratios.

The researchers observed a correlation between higher 25(OH)D concentration and lower case-fatality rates after breast cancer diagnosis. Compared with patients in the lowest quintile of 25(OH)D, those in the highest quintile had about half the death rate from breast cancer (hazard ratio, 0.56).

"High serum 25(OH)D was associated with lower mortality from breast cancer. Serum 25(OH)D in all patients with breast cancer should be restored to the normal range (30 to 80 ng/mL), with appropriate monitoring," the authors write. "Clinical or field studies should be initiated to confirm that this association was not due to reverse causation."

Abstract
Full Text

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.